The Swiss voice in the world since 1935

Novartis has to include new risks for anti-cancer wonderdrug Kymriah

building novartis
Keystone / Georgios Kefalas

The American regulator now requires the Swiss pharma giant to include new risks for its immunotherapy for acute lymphoblastic leukaemia.

The US Food and Drug Administration (FDA) is forcing producers of immunotherapies based on genetically modified autologous T lymphocytes (CAR-T), including Novartis, which pioneered the field with its Kymriah (tisagenlecleucel), to include new risks in the package leaflets accompanying these treatments.

In a publication published on Monday evening, the FDA points out that it has identified new risks of T-cell cancer since the approval of Kymriah at the end of August 2017, which could require hospitalisation or even lead to the death of treated patients. The authority stresses that this is “new safety information” and considers that it applies to all CAR-Ts targeting the BCMA- and CD19 proteins.

More

At the end of last year, the regulator announced that it was conducting an investigation into this type of treatment, produced by Novartis as well as Gilead Sciences, Johnson and Johnson and Kite Pharma, among others.

Novartis caused a sensation on August 30, 2017 when it obtained the green light in the US to market a first-ever cellular immunotherapy for acute lymphoblastic leukaemia (ALL). At the time, the price of the treatment was set at $475,000.


This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here

If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.


External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Daily news

Get the most important news from Switzerland in your inbox.

Daily

The SBC Privacy Policy provides additional information on how your data is processed.


Popular Stories

Most Discussed

News

Nestlé: French authorities order withdrawal of filtration

More

French authorities order Nestlé to remove its filtration system

This content was published on Authorities in the south of France have served formal notice to Nestlé Waters, a subsidiary of the Swiss food giant, to "withdraw within two months" its microfiltration system for its Perrier mineral water.

Read more: French authorities order Nestlé to remove its filtration system
The referendum against the introduction of the e-ID is successful

More

Switzerland to hold referendum on introducing electronic ID

This content was published on The Swiss are set to vote on the introduction of e-ID after the Federal Chancellery confirmed enough valid signatures were submitted by opponents of the federal law on electronic identity.

Read more: Switzerland to hold referendum on introducing electronic ID

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR